Wenxin Keli versus Sotalol for Paroxysmal Atrial Fibrillation Caused by Hyperthyroidism: A Prospective, Open Label, and Randomized Study
Table 6
Comparisons of thyroid hormones at any follow-up time-points in the second investigation.
Baseline
WK* treatment (54 cases)
Sotalol treatment (54 cases)
Control (55 cases)
value ( value)**
FT3* (pmol/L)
5.532 ± 2.372
5.752 ± 2.608
5.680 ± 2.486
0.110 (0.896)
FT4* (pmol/L)
18.469 ± 7.182
19.351 ± 7.577
19.046 ± 7.576
0.195 (0.823)
TSH* (IU/mL)
7.126 ± 10.449
5.859 ± 8.668
6.832 ± 10.110
0.249 (0.780)
Three months
WK* treatment (54 cases)
Sotalol treatment (54 cases)
Control (55 cases)
value ( value)**
FT3* (pmol/L)
5.035 ± 0.934
5.129 ± 0.908
5.098 ± 0.965
0.140 (0.870)
FT4* (pmol/L)
15.664 ± 3.112
16.061 ± 3.336
15.994 ± 3.465
0.222 (0.801)
TSH* (IU/mL)
4.683 ± 4.211
4.083 ± 3.456
4.352 ± 3.885
0.326 (0.722)
Six months
WK* treatment (54 cases)
Sotalol treatment (54 cases)
Control (55 cases)
value ( value)**
FT3* (pmol/L)
5.257 ± 0.930
5.373 ± 0.915
5.381 ± 1.057
0.277 (0.758)
FT4* (pmol/L)
16.446 ± 3.339
16.916 ± 3.727
16.955 ± 4.014
0.317 (0.729)
TSH* (IU/mL)
4.032 ± 3.492
3.567 ± 2.885
3.756 ± 3.202
0.288 (0.750)
Nine months
WK* treatment (54 cases)
Sotalol treatment (54 cases)
Control (55 cases)
value ( value)**
FT3* (pmol/L)
5.367 ± 0.975
5.458 ± 0.958
5.590 ± 1.328
0.566 (0.569)
FT4* (pmol/L)
17.184 ± 3.208
17.760 ± 4.131
18.084 ± 4.833
0.668 (0.514)
TSH* (IU/mL)
2.912 ± 1.730
2.701 ± 1.666
2.785 ± 1.719
0.211 (0.810)
Twelve months
WK* treatment (54 cases)
Sotalol treatment (54 cases)
Control (55 cases)
value ( value)**
FT3* (pmol/L)
5.562 ± 0.969
5.740 ± 1.302
5.874 ± 1.406
0.866 (0.422)
FT4* (pmol/L)
17.830 ± 3.485
18.532 ± 5.113
18.901 ± 5.388
0.716 (0.490)
TSH* (IU/mL)
2.519 ± 1.420
2.388 ± 1.423
2.409 ± 1.488
0.129 (0.879)
WK: Wenxin Keli, FT3: free triiodothyronine, FT4: free thyroxine, and TSH: thyroid stimulating hormone; **analyzed by one-way analysis of variance and least significant difference test.
